About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Selective PDE4D Inhibitor Shows Promise in Treating Fragile X

by Anjali Aryamvally on November 8, 2017 at 4:03 PM
Font : A-A+

Selective PDE4D Inhibitor Shows Promise in Treating Fragile X

New study suggests the se of BPN14770, as a potential treatment for Fragile X Syndrome (FXS) and possibly other autism spectrum disorders. BPN14770 is currently under development by Tetra Discovery Partners as a prospective treatment for memory and cognitive problems associated with Alzheimer's disease.

Daily treatment of adult male fmr1 C57B16 knockout mice (a standard FXS animal model) for 14 days reduced hyperarousal, and improved social interactions and increased natural behaviors such as nesting and marble burying compared to control FXS mice that received a placebo. At the same time, there was no deleterious effect on behavioral scores in normal wild-type mice treated with BPN14770. The behavioral benefits of BPN14770 in the FXS mice endured for two weeks after drug washout. Microscopic analysis of neurons in the prefrontal cortex from the treated FXS mice showed an improvement in dendritic spine morphology; this finding, combined with the 11 hour half-life of BPN14770 in mice, suggests that the enduring treatment benefits of BPN14770 were not due to slow washout of the drug.

Advertisement


The new research was published in Scientific Reports, an online, open-access primary research publication from the publishers of Nature by Tetra Discovery Partners and the company's research collaborators.

"This preclinical study strongly supports PDE4D as a therapeutic target for the treatment of FXS," said Mark E. Gurney, Ph.D., Chairman and Chief Executive Officer of Tetra Discovery Partners. "We have already demonstrated evidence of human safety and tolerability for BPN14770 in a Phase 1 study in healthy young and elderly volunteers. This research suggests BPN14770 may also have utility in the treatment of FXS, which is associated with a spectrum of neuropsychiatric symptoms, mild to severe cognitive impairment and intellectual disability, and potentially also find use in the treatment of other conditions on the autism spectrum."
Advertisement

"The results from these studies are very promising," commented Michael Tranfaglia, M.D., Medical Director and Chief Scientific Officer of the FRAXA Research Foundation. "Inhibition of PDE4 has been validated as a treatment strategy by many research groups in the Fragile X field. However, the current study demonstrates the enhanced therapeutic potential of PDE4D inhibition with BPN14770, which shows the ability to rescue major Fragile X phenotypes not only in acute dosing, but in chronic dosing as well.

"Furthermore, the significant carryover of BPN14770 effects, even two weeks after treatment suggests this drug candidate has genuine long-term beneficial effects on Fragile X pathology," Dr. Tranfaglia continued. "Additionally, tolerance has been a major problem with other drug classes studied as potential treatments for Fragile X syndrome, such as mGluR5 NAMs and GABA-B agonists, but no tolerance was been seen in studies with BPN14770. The selective nature of this compound, which targets only PDE4D, also greatly improves the tolerability of the drug over past-studied, general PDE4 inhibitors, which should facilitate clinical trials in this difficult-to-treat population."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
Long-Term Glycemic Control - A Better Measure of COVID-19 Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Ehlers-Danlos syndrome 

Recommended Reading
Fragile X Syndrome
Fragile X syndrome is an inherited X-linked genetic disorder that results in developmental and ......
Children With Fragile X Syndrome Have a Bias Toward Threatening Emotion
Infants and children with FXS show bias toward threatening emotion, rather than positive emotion, a ...
Debunking the Myth That 'Fragile X Syndrome' Cannot be Treated
The awareness level about fragile X Syndrome in India with respect to other countries is ......
Better Measurement Tools Required To Treat Fragile X Syndrome
Newer outcome and assessment tools need to be developed for more rapid clinical trials to serve as ....
Ehlers-Danlos syndrome
Ehlers-Danlos syndrome is a group of inherited disorders that affect the connective tissues of the s...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use